Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

219.72 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

23 24 Next >

Tesla's India Move, Adidas Receives Orders For Massive Unsold Yeezy Inventory, Spotify Raises Subscription Prices: Today's Top Stories ↗

July 24, 2023

Wall Street Journal

Via Benzinga

Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy ↗

July 24, 2023

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to

Via Benzinga

Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk

July 24, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Analyst Ratings for Alnylam Pharmaceuticals ↗

June 22, 2023

Via Benzinga

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today ↗

June 21, 2023

Via Benzinga

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years ↗

June 16, 2023

Via Benzinga

Why Shares of BridgeBio Pharma Skyrocketed This Week ↗

July 21, 2023

The biotech company saw strong results in a phase 3 trial.

Via The Motley Fool

Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results

July 20, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine

July 19, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

What 10 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

May 31, 2023

Via Benzinga

Looking Into Alnylam Pharmaceuticals's Recent Short Interest ↗

May 10, 2023

Via Benzinga

$1000 Invested In This Stock 15 Years Ago Would Be Worth $7,600 Today ↗

May 05, 2023

Via Benzinga

Where Alnylam Pharmaceuticals Stands With Analysts ↗

May 05, 2023

Via Benzinga

Why Alnylam Pharmaceuticals Topped the Market Today ↗

July 17, 2023

Monday was a good day for biotechs fighting the good fight against a common degenerative brain disorder.

Via The Motley Fool

Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 17, 2023

Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived...

Via Benzinga

Alnylam Says Single Injection Of RNAi Therapy Cuts Alzheimer's-Linked Proteins By 65%, Stock Soars ↗

July 17, 2023

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced updated interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP for Alzheimer's disease and

Via Benzinga

Alnylam Clocks ~50% Revenue Growth In Q1 On Solid Commercial Execution ↗

May 04, 2023

Via Benzinga

BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease ↗

July 17, 2023

The companies are working on treatments for a leading cause of heart failure.

Via Investor's Business Daily

Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

July 17, 2023

From Alnylam Pharmaceuticals

Via Business Wire

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years ↗

July 14, 2023

Via Benzinga

Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

June 30, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities ↗

June 17, 2023

The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...

Via Talk Markets

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 09, 2023

Via Benzinga

Another Patent Dispute Emerges: Small Biotech Firm Sues Moderna, Pfizer, and BioNTech Over COVID-19 Vaccine Tech ↗

June 07, 2023

Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) were named in lawsuits by

Via Benzinga

Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference

June 05, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

Analyst Says Alnylam's New Patisiran Data Shows Disease Slowing With Early Intervention, But Survival Benefit Remains Of Interest ↗

May 22, 2023

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) released new results from an interim analysis of exploratory data from the open-label extension (OLE) period of the APOLLO-B Phase 3 study of patisiran, for...

Via Benzinga

Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

May 20, 2023

From Alnylam

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2023 ↗

May 05, 2023

Via Benzinga

Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity

May 04, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.